Khartis raises $95.0M (Aug 2026)
Find the investors funding Health rounds
326,000+ verified VCs, angels and family offices — direct emails, check sizes and stage filters.
Khartis bags USD 95m for oral challenger to Tepezza - AllSci
Khartis is a biopharmaceutical company focused on developing innovative oral therapies. The company aims to provide effective alternatives to existing treatments, specifically targeting conditions treated by Tepezza. This funding round will support their efforts in advancing their oral challenger to Tepezza.
Khartis bags USD 95m for oral challenger to Tepezza AllSci
| Sep 02, 2026 | Thyme Care | $125.0M | Series E | United States |
| Sep 02, 2026 | DocPharma | $2.0M | Pre-Series A | India |
| Sep 02, 2026 | GonGlobal | $1.2M | Seed | Australia |
| Sep 01, 2026 | Norbert Health | $14.0M | Series A | United States |
Find the investors behind rounds like this one
You just read who funded Khartis. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.